Investors pour capital into fewer, larger rounds as exits lag and AI adoption accelerates
Canada’s health-technology investment market staged a notable rebound in 2025, but the recovery was narrow with capital flowing into fewer companies, larger financings and later-stage opportunities.
That’s the central takeaway from Pender Ventures’ Canadian Health Tech Funding and Trends Report 2025 Year in Review, which reveals cautious optimism rather than a broad-based resurgence even as total disclosed funding in the industry reached approximately $1.3 billion in 2025, marking a sharp increase from the prior year.
READ: Why did last year see an unprecedented surge in healthcare private equity?
Beneath the headline growth the number of financings fell significantly, highlighting an environment where investors concentrated their bets on companies perceived to have lower risk, clearer regulatory pathways and stronger commercial traction.
Average deal sizes more than doubled over the year, reinforcing the shift toward later-stage and medtech-focused rounds. Early-stage ventures continued to face a difficult fundraising climate, suggesting the innovation pipeline remains under pressure even as mature companies secure sizable capital injections.
The result is a market that rewards proven execution while leaving emerging startups scrambling for runway.
Exit conditions remain a critical pressure point for the sector and despite the jump in funding, liquidity events stayed limited.
The report characterizes exits as the “system’s primary pressure point,” pointing to a gap between capital deployment and realized returns. A handful of larger mergers and acquisitions helped lift overall exit values, but the broader landscape still lacks consistent transaction flow. For investors, that imbalance underscores ongoing uncertainty around timelines for monetization.
Cross-border capital played an outsized role in shaping the year’s results. US investors participated in a minority of total deals but accounted for the vast majority of disclosed dollars. This trend highlights how Canadian health-tech firms increasingly rely on foreign capital to scale, particularly for later-stage growth rounds. It also signals that international players continue to see value in Canadian innovation, even as domestic funding remains selective.
AI remains a dominant theme across healthcare innovation, but expectations are becoming more demanding.
AI tools are now embedded in clinical workflows, diagnostics and decision-support systems, reflecting growing adoption across healthcare infrastructure. Still, the report notes that “AI Companies are yet to Demonstrate their Financial ROI,” reinforcing that novelty alone no longer attracts capital. Financial performance, measurable savings and proven revenue models are becoming essential.
Shifts in thematic investment also emerged during the year. Employer-driven demand for longevity and preventative care solutions gained momentum, while women’s health attracted growing attention as a dedicated investment category. These segments reflect changing healthcare priorities and offer new growth avenues for companies able to link improved outcomes with cost efficiency.
Overall, 2025 delivered a rebound in funding dollars but not a return to easy capital. Investors displayed discipline, prioritizing scale, validation and commercialization over experimentation. With exit markets still constrained and early-stage financing tight, the Canadian health-tech ecosystem remains in a selective growth phase.
For market watchers, the message is that opportunity exists, but it increasingly favours companies that can prove clinical relevance, economic value and a realistic path to liquidity. The sector’s next chapter will depend not just on innovation, but on execution.
